Research Analysts Offer Predictions for ACHV FY2026 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Equities research analysts at HC Wainwright increased their FY2026 EPS estimates for Achieve Life Sciences in a research note issued to investors on Wednesday, March 25th. HC Wainwright analyst B. Folkes now forecasts that the biopharmaceutical company will post earnings per share of ($1.28) for the year, up from their previous forecast of ($1.35). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ FY2027 earnings at ($1.24) EPS, FY2028 earnings at $0.36 EPS, FY2029 earnings at $1.52 EPS and FY2030 earnings at $2.31 EPS.

Achieve Life Sciences (NASDAQ:ACHV) last posted its quarterly earnings data on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01).

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

Achieve Life Sciences Stock Performance

Shares of NASDAQ:ACHV opened at $2.65 on Friday. Achieve Life Sciences has a 12-month low of $1.84 and a 12-month high of $6.03. The company’s 50 day moving average price is $4.31 and its two-hundred day moving average price is $4.29. The firm has a market cap of $141.07 million, a PE ratio of -2.04 and a beta of 1.81. The company has a quick ratio of 5.14, a current ratio of 4.39 and a debt-to-equity ratio of 0.52.

Hedge Funds Weigh In On Achieve Life Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. raised its position in Achieve Life Sciences by 18,747.4% in the fourth quarter. Franklin Resources Inc. now owns 4,369,193 shares of the biopharmaceutical company’s stock valued at $21,715,000 after purchasing an additional 4,346,011 shares during the last quarter. Hudson Bay Capital Management LP bought a new stake in shares of Achieve Life Sciences during the second quarter worth about $2,652,000. Millennium Management LLC increased its stake in shares of Achieve Life Sciences by 472.3% in the fourth quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company’s stock valued at $6,755,000 after buying an additional 1,121,614 shares during the period. Pathstone Holdings LLC bought a new position in Achieve Life Sciences in the 3rd quarter valued at approximately $1,581,000. Finally, KVP Capital Advisors LP bought a new position in Achieve Life Sciences in the 4th quarter valued at approximately $2,298,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

More Achieve Life Sciences News

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $12 target while materially boosting long‑range EPS forecasts (FY2029 and FY2030 upgrades), signaling confidence in ACHV’s longer‑term commercial potential. Achieve Life Sciences (NASDAQ:ACHV) Earns Buy Rating from HC Wainwright
• Positive Sentiment: A peer‑reviewed publication linked cytisinicline’s receptor profile to low nausea and favorable tolerability, a clinical differentiator that could support uptake if approved. Publication in Nicotine & Tobacco Research
• Positive Sentiment: Analysts and commentators are highlighting the upcoming PDUFA (June 20, 2026) and planned Phase 3 vaping cessation trial (ORCA‑V2 in 1H 2026) as major value catalysts toward a possible 1H‑2027 commercial launch if approved. Achieve Life Sciences: Maintaining ‘Buy’ On Upcoming PDUFA…
• Positive Sentiment: Unusually large retail/institutional activity in call options suggests speculative bullish positioning ahead of the PDUFA and other near‑term catalysts. Investors Purchase Large Volume of Call Options on Achieve Life Sciences
• Neutral Sentiment: HC Wainwright also updated quarter‑by‑quarter 2026 EPS estimates (small quarterly losses expected) while keeping the Buy stance — important for modeling near‑term cash needs but not a directional change to the thesis. MarketBeat ACHV coverage
• Neutral Sentiment: The company’s Q4 2025 transcript and summary show a modest EPS miss and operational detail; useful for context on execution but not a game‑changer versus the upcoming FDA decision. Q4 2025 earnings call transcript Q4 2025 Earnings Call Summary
• Negative Sentiment: Mixed analyst revisions include downgrades to mid‑term EPS (HC Wainwright trimmed FY2027 and FY2028; Zacks cut FY2026/FY2027), which raises uncertainty on near‑term profitability and could pressure the stock ahead of the PDUFA. Market analyst estimate changes

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.